Across TCGA pan-cancer cohorts, ZKSCAN4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZKSCAN4 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZKSCAN4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZKSCAN4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where ZKSCAN4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.722	0.229	.006	21	view →
LUAD	DFS	Median	All	1.000	0.380	.003	9	view →
UCEC	OS	Median	III,IV	0.484	1.000	.031	8	view →
HNSC	OS	Tertile	III,IV	0.776	0.315	.038	7	view →
OV	DFS	Median	All	0.884	0.603	.049	4	view →
LSCC	DFS	Median	II,III,IV	0.823	0.533	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: ZKSCAN4 tumor-vs-normal RNA expression · all ZKSCAN4 data types